These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 19610078)

  • 1. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.
    Kato GJ; Hebbel RP; Steinberg MH; Gladwin MT
    Am J Hematol; 2009 Sep; 84(9):618-25. PubMed ID: 19610078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
    Kato GJ; Gladwin MT
    JAMA; 2008 Dec; 300(22):2638-46. PubMed ID: 19066384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leg ulcers in sickle cell disease.
    Minniti CP; Eckman J; Sebastiani P; Steinberg MH; Ballas SK
    Am J Hematol; 2010 Oct; 85(10):831-3. PubMed ID: 20872960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sickle cell disease at the dawn of the molecular era.
    Abboud MR; Musallam KM
    Hemoglobin; 2009; 33 Suppl 1():S93-S106. PubMed ID: 20001639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sickle cell disease, vasculopathy, and therapeutics.
    Kassim AA; DeBaun MR
    Annu Rev Med; 2013; 64():451-66. PubMed ID: 23190149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular complications of sickle cell disease.
    Usmani A; Machado RF
    Clin Hemorheol Microcirc; 2018; 68(2-3):205-221. PubMed ID: 29614633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin in renal injury due to sickle cell disease.
    Tharaux PL
    Contrib Nephrol; 2011; 172():185-199. PubMed ID: 21893999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravascular hemolysis and the pathophysiology of sickle cell disease.
    Kato GJ; Steinberg MH; Gladwin MT
    J Clin Invest; 2017 Mar; 127(3):750-760. PubMed ID: 28248201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.
    Kato GJ; Gladwin MT; Steinberg MH
    Blood Rev; 2007 Jan; 21(1):37-47. PubMed ID: 17084951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasculopathy and pulmonary hypertension in sickle cell disease.
    Potoka KP; Gladwin MT
    Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L314-24. PubMed ID: 25398989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa.
    Dubert M; Elion J; Tolo A; Diallo DA; Diop S; Diagne I; Sanogo I; Belinga S; Guifo O; Wamba G; Ngo Sack F; Boidy K; Kamara I; Traore Y; Diakite CO; Gbonon V; Faye BF; Seck M; Deme Ly I; Chelo D; N'Guetta R; Diop IB; Gaye B; Jouven X; Ranque B
    Blood; 2017 Nov; 130(20):2215-2223. PubMed ID: 28931524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.
    Conran N; Franco-Penteado CF; Costa FF
    Hemoglobin; 2009; 33(1):1-16. PubMed ID: 19205968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.
    Hebbel RP; Osarogiagbon R; Kaul D
    Microcirculation; 2004 Mar; 11(2):129-51. PubMed ID: 15280088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.
    Gladwin MT; Kato GJ
    Hematology Am Soc Hematol Educ Program; 2005; ():51-7. PubMed ID: 16304359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
    Kato GJ; McGowan V; Machado RF; Little JA; Taylor J; Morris CR; Nichols JS; Wang X; Poljakovic M; Morris SM; Gladwin MT
    Blood; 2006 Mar; 107(6):2279-85. PubMed ID: 16291595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sickle cell disease vasculopathy: a state of nitric oxide resistance.
    Wood KC; Hsu LL; Gladwin MT
    Free Radic Biol Med; 2008 Apr; 44(8):1506-28. PubMed ID: 18261470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
    Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT
    Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of vasculopathy in sickle cell disease and thalassemia.
    Morris CR
    Hematology Am Soc Hematol Educ Program; 2008; ():177-85. PubMed ID: 19074078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial dysfunction in Sickle Cell Disease: Strategies for the treatment.
    Pavan AR; Terroni B; Dos Santos JL
    Nitric Oxide; 2024 Aug; 149():7-17. PubMed ID: 38806107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.